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Abstract
Background: Tumor-derived soluble factors, including soluble HLA molecules, can contribute to cancer immune escape and
therefore impact on clinical course of malignant diseases. We previously reported that melanoma cells produce, in vitro,
soluble forms of the non-classical MHC class I molecule HLA-E (sHLA-E). In order to investigate sHLA-E production by various
tumors and to address its potential value as a tumor-associated marker, we developed a specific ELISA for the quantification
of sHLA-E in biological fluids.
Methodology/Principal Findings: We developed a sHLA-E specific and sensitive ELISA and we showed that serum sHLA-E
levels were significantly elevated (P,0.01) in melanoma patients (n=127), compared with healthy donors (n=94). sHLA-E
was also detected in the culture supernatants of a wide variety of tumor cell lines (n=98) including melanomas, kidney,
colorectal and breast cancers. Cytokines regulation of sHLA-E production by tumor cells was also carried out. IFN-c, IFN-a
and TNF-a were found to upregulate sHLA-E production by tumor cells.
Conclusions/Significance: In view of the broad tumor tissue release of HLA-E and its up-regulation by inflammatory
cytokines, sHLA-E should be studied for its involvement in immune responses against tumors. Interestingly, our results
demonstrated a positive association between the presence of serum sHLA-E and melanoma. Therefore, the determination of
sHLA-E levels, using ELISA approach, may be investigated as a clinical marker in cancer patients.
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Introduction
Evidences accumulated demonstrate the ability of the immune
system to identify and destroy malignant cells, in order to prevent
tumor development. This process called cancer immunosurveil-
lance, is based on the joined action of the effectors of innate (NK,
NKT cells, cd T cells, and dendritic cells) and adaptive (antigen-
specific T and B cells) immunity to sense and eradicate nascent-
transformed cells. However, despite the existence of well-defined
immunogenic tumor antigens, and even in the presence of tumor-
antigen-specific cytotoxic T cells, the immune system does not
seem to be fully effective in eradicating tumors [1].
Several mechanisms have been implicated in tumor immune
escape, including structural and functional alterations of the
Human Leukocyte Antigens (HLA), which represent frequent
events in cancers. This include classical HLA class I antigen (HLA-
A, -B, -C) loss or downregulation and aberrant expression of non-
classical HLA class I antigens (HLA-E, -G), providing mechanisms
leading to a decrease in recognition and destruction of tumor cells
by immune cytotoxic effectors (mainly CTL and NK cells) [2].
Interest in non-classical HLA molecules has been stimulated by the
demonstration that they may contribute to NK and T cell tumor
cell escape through their interaction with NK inhibitory receptors
[3–6]. Furthermore, production of non-cell bound soluble HLA
(sHLA) molecules has also been described and may represent an
alternative strategy for cancer immune escape [7,8]. In support of
this hypothesis, sHLA molecules have been shown to induce in vitro
inhibition and/or apoptosis of CTL and NK [9,10]. Moreover,
increased serum levels of classical and non-classical sHLA have
been described in several malignant diseases, and their prognostic
relevance is suggested by statistically significant association with
high stage disease or with particular clinical course in various
malignancies [11].
We previously observed, in collaboration with pathologists, a
frequent expression of HLA-E by melanomas and colon
carcinomas [12]. Studies from our group and others supported
an immunosuppressive potential of this expression, through
engagement of the CD94/NKG2A inhibitory NKR on cytotoxic
cells (NK and CD8 TIL) by tumor cell membrane HLA-E [13–
16]. We also reported that melanoma cell lines can produce
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shedding of surface molecules, and that this production was
increased by IFN-c [12].
The aim of the present project was to develop an ELISA assay for
the detection and the quantification of sHLA-E in biological fluids,
to validate its specificity and, if adequate, to address the clinical
significance of sHLA-E levels in the blood of melanoma patients.
Results
Development of an HLA-E specific ELISA
To detect and quantify sHLA-E in biological samples, we
develop a sandwich ELISA using noncompeting solid capture and
biotinylated detection anti-HLA-E monoclonal antibodies MEM-
E/08 and MEM-E/07 respectively. First a concentration range of
a purified recombinant soluble HLA-E (rsHLA-E) was tested. A
shown on Figure 1A, rsHLA-E was detected at a minimum
concentration of 5 pg/ml. Given the reported cross-reactivity of
both anti-HLA-E Abs with four HLA class Ia allelic forms: HLA-
A23, -B7, -B8 and -B27, we then checked their detection using our
designed ELISA assay. Among recombinant soluble HLA-A23,
-B7, -B8 and -B27 as well as rsHLA-A2 used as negative control,
only a weak signal was obtained with rsHLA-B7 at the maximal
dose 20 ng/ml (Fig. 1B).
These results led to the conclusion that the sandwich ELISA
described here is highly specific and sensitive for HLA-E and could
be used as a screening method for the detection of sHLA-E in
biological samples.
Increased soluble HLA-E in sera of melanoma patients
We screened sera from 94 healthy donors and 127 melanoma
patients without current therapy for the presence of sHLA-E
(Table 1). We detected sHLA-E in serum samples from both
healthy and patient donors in a dilution-dependent manner
(Fig. 2A) demonstrating that this ELISA could be used to quantify
sHLA-E in sera samples. Considering the possible incidence of age
and the gender, no significant differences in sHLA-E levels were
observed (data not shown). The individual values of serum sHLA-
E are presented on a dot-plot using a log scale (Fig. 2B) and means,
medians and ranges are indicated on Table 2.
In melanoma patients, serum levels of sHLA-E (median [range])
were significantly increased compared with those in healthy
Figure 1. Sensitivity and specificity of sHLA-E ELISA. A/ Detection of sHLA-E using serial dilutions of recombinant HLA-E monomer. The grey
area indicates the range of measurable sHLA-E levels. B/ Determination of the HLA-E binding specificity. Serial dilutions of HLA-A2, -A23, -B7, -B8 and
-B27 recombinant soluble monomers have been tested in comparison with recombinant HLA-E monomer.
doi:10.1371/journal.pone.0021118.g001
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p,0.001). To quantify the frequency of sHLA-E-positive sera, we
take a cut-off value of 5 pg/ml. This analysis revealed that in the
group of 94 healthy donors, sHLA-E could be detected in 30 sera
(31.9% of total). In contrast, in melanoma patients, 68 out of 127
sera (53.5% of total) contained sHLA-E (Fig. 2C). Thus,
percentages of positive sera were significantly higher in melanoma
patients compared to healthy donors (p,0.001). Subgroup
analysis considering AJCC stages (American Joint Committee on
Cancer, http://www.cancerstaging.org/) was then performed. No
relationship of serum sHLA-E levels was found with respect to
tumor grading (Fig. 2D). However, as shown in Table 1, sHLA-E
levels were significantly increased in stage III melanoma patients
compared with healthy donors (p,0.0001).
Together, these results validated an ELISA for the determina-
tion of sHLA-E in human serum and demonstrated that sHLA-E is
significantly increased in sera of melanoma patients.
Production of soluble HLA-E by a diverse panel of human
tumor cell lines
We analyzed the production of soluble HLA-E by 98 different
established human tumor cell lines, representing solid tumors as
melanomas (n=30), carcinomas (cancers of the lung (n=5), colo-
rectum (n=12), kidney (n=10), ovary (n=3), breast (n=11) and
prostate (3)), thyroid cancer (n=1), cervix cancer (n=1), sarcomas
(osteosarcomas, n=3), gliomas (n=2) and liquid tumors (meso-
theliomas (n=7), myelomas (n=7) and leukemias (n=3)). As
shown in Figures 3A and 3B (in white), sHLA-E was detected in
the supernatants of tumor cell lines derived from all origins tested,
excepted in the supernatant of ovary tumor, myeloma, leukemias
Table 1. Characteristics of healthy donors and melanoma
patients studied.
N6 of
cases Age Gender
Mean Median Range Male Female
Healthy donors 94 42.5 44 19–67 46 48
Melanoma patients 127 55 54.5 20–88 81 46
doi:10.1371/journal.pone.0021118.t001
Figure 2. Analysis of sHLA-E in sera of healthy controls and melanoma patients. A/ Illustrative detection of sHLA-E using serial dilutions of
two serum samples by ELISA. B/ Distribution of soluble HLA-E concentrations in sera of healthy controls and melanoma patients. P-value indicates the
difference between the two groups. C/ Percentages of positive sHLA-E sera (sHLA-E$5 pg/ml) in healthy donors and melanoma patients. D/
Distribution of soluble HLA-E concentrations in sera of melanoma patients with regard of tumor stages.
doi:10.1371/journal.pone.0021118.g002
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conditions (500 000 cells, in 3 ml, during 48 h), the levels of
sHLA-E naturally produced by tumor cell lines were ranging from
5 to 400 pg/ml. Highest productions were detected among
melanoma, colorectal and kidney tumor cells lines. The frequency
analysis of the tumor cell lines able to produce sHLA-E (taking a
cut-off value of 5 pg/ml) revealed that about one third of the
tumor cell lines produced sHLA-E (24.5%, 24 out of 98) with
higher percentages obtained in melanoma (40%, 12 out of 30) and
renal cell carcinoma (40%, 4 out of 10) (Fig. 3C).
Selective regulation of sHLA-E production by cytokines
We have previously shown that IFN-c increased the surface
expression of HLA-E and the shedding of soluble HLA-E by
melanoma cells. To confirm this result and broaden the panel of
tested cytokines, the effect of IL-1b, IL-2, IL-4, IL-6, IL-7, IL-10,
IL-12, IL-13, IL-15, IL-23, IFN-a2a, IFN-c, TNF-a and GM-CSF
upon tumor cells lines sHLA-E production was tested. As
expected, sHLA-E release was induced or significantly increased
in tumor cell supernatants after IFN-c activation (p,0.0001). The
frequency analysis of the tumor cell lines able to produce sHLA-E
after IFN-c treatment doubled (from 24.5% to 49%, 48 out of 98)
(Fig. 3C). To a lesser extent, exposure to IFN-a and TNF-a
significantly increased the production of sHLA-E by tumor cell
lines (p,0.001 and p,0.05 respectively). These results are
illustrated in Figure 4A using two melanoma cell lines (M88 and
M102) and one colon adenocarcinoma cell line (HT29). Other
tested cytokines have no effect on this production. Kinetic analysis
and dose-response experiments were performed with IFN-c, IFN-
a and TNF-a. As shown in Figure 4B, sHLA-E production was
significantly increased in a dose-dependent manner with the
maximal effect observed with 10 ng/ml for the three cytokines.
This production was detectable as early as 1 day following
cytokines treatment of tumor cells and was maximal after 48 hours
(Fig. 4C).
Discussion
This study provides evidence that serum sHLA-E is significantly
increased in patients suffering from melanoma compared to
normal individuals, independently of age and gender. We carried
this analysis through, using a specific and sensitive ELISA that we
developed and validated for the determination of sHLA-E levels in
biological fluids. In this large study including 221 individuals, we
observed elevated concentrations of serum sHLA-E, as well as
higher frequency of sHLA-E positive sera in patients with
melanomas compared with healthy donors. Considering the
tumor grading, while sHLA-E levels seemed to ascend with
advanced disease stages until stage III, we did not find significant
association between serum sHLA-E levels and melanoma stage,
which may be caused by the inequitable repartition of patients by
subgroup. However, if compared to healthy donors, patients with
stage III melanoma exhibited highly elevated sHLA-E serum level
in terms of both concentration and frequency of positive sera. On
the other hand, patients with stage IV disease exhibited lower
levels of sHLA-E, which is in accordance with the faint
spontaneous expression of HLA-E by metastatic tumor sections
that we previously reported by immunohistochemistry [12].
These data emphasized the interest for soluble non-classical
HLA-I molecules in malignant diseases. Another non-classical
HLA-I molecule, HLA-G, has been identified in diverse
malignancies including cancers and has received a lot of attention
in recent publications. Clinical studies demonstrated that sHLA-G
levels were significantly elevated in sera of patients with malignant
melanomas, gliomas, breast and ovarian cancers, non-small-cell-
lung cancers (NSCLC), chronic lymphocytic leukemias, B cell and
T cell Non-Hodgkin’s lymphomas [17–21]. Moreover, Zhu et al.
demonstrated that serum sHLA-G levels could be a useful
indicator in distinguishing colorectal cancers from benign
colorectal diseases [22]. Finally, sHLA-G levels were also
significantly higher in malignant ascites of ovarian and breast
carcinomas than in benign controls [23]. Similarly, elevated levels
of the stress-inducible MHC class I chain-related surface
glycoproteins, MICA and MICB, have been found to correlate
with cancer stages and metastasis in several carcinomas [24–26].
Altogether, these studies congruently revealed increased amounts
of non classical HLA-I molecules in biological fluids (blood and
ascite) of patients suffering from various cancers.
Given the fact that we and others have previously detected
sHLA-E in the supernantants of melanoma and colorectal cell
lines by Western blot analysis, we investigated, using our designed
ELISA, the production of sHLA-E by tumor cell lines derived
from major tumor categories, including solid tumors as melanoma,
cancers of the breast, colon and kidney and liquid tumors as
mesotheliomas and myelomas [12,27]. We showed that sHLA-E is
spontaneously produced by 25% of tested cell lines (24 out of 98),
derived from several types of human tumors, especially from
melanoma, colorectal and kidney cancers. So, it will be interesting
to address the potential predictive and prognostic value of sHLA-E
levels in the blood of patients suffering from these cancers.
Table 2. sHLA-E in sera of healthy donors and melanoma patients studied.
N6 of cases sHLA-E (pg/ml) Positive sHLA-E sera (%)
*
Mean Median Range
Healthy donors 94 61.6 0 0–1224 31.9
Melanoma patients 127 72.6** 9 0–2544 53.5**
Stage I 25 34.9 9 0–361 52
Stage II 18 28.9 12.5 0–202 55.6
Stage III 58 109.7** 21 0–2544 60***
Stage IV 23 17.2 0 0–124 34.8
**p,0.01,
***p,0.001.
p-values indicate the differences between healthy controls and the patient groups.
*Sera are considered as positive if sHLA-E levels are higher than or equal to 5 pg/ml.
doi:10.1371/journal.pone.0021118.t002
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treated or not by IFN-c with regard of tumor origins: distribution of individual concentrations (A), mean levels (B) and percentages of positive
supernatants (sHLA-E$5 pg/ml) (C).
doi:10.1371/journal.pone.0021118.g003
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21118Figure 4. Influence of cytokines on sHLA-E production by tumor cells. A/ sHLA-E detection in supernatants of three tumor cell lines: two
melanoma cell lines (M88 and M102) and one colocarcinoma cell line (HT29), treated or not with IFN-a, IFN-c or TNF-a (10 ng/ml, 48 h). Significant
differences between the control and treatment values are indicated (*p,0.05, **p,0.01, ***p,0.001). B/ sHLA-E detection in culture supernatants of
M102 treated with serial concentrations of IFN-a, IFN-c and TNF-a for 48 h. C/ Time course of sHLA-E production in culture supernatant of M102
treated for up to 6 days with 10 ng/ml IFN-c.
doi:10.1371/journal.pone.0021118.g004
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HLA-E production by tumor cell lines. According to our previous
results on melanoma cell lines [12], we showed that IFN-c induced
or increased sHLA-E production, leading to the production of
sHLA-E by 50% of the tumor cell lines tested (48 out of 98).
Moreover, release of sHLA-E was also driven by IFN-a and TNF-
a in a lesser extent. Considering that IFN-c and IFN-a are high
inducers of HLA-I molecules expression, their impact upon sHLA-
E production likely reflect the increase of HLA-E expression by
tumor cells. Since sHLA-E release by melanoma cells is mainly
matrix metalloproteinase-dependant, TNF-a effect on HLA-E
production could be due to the ability of TNF-a to promote matrix
metalloproteinase expression [12,28]. These results are consistent
with those of Coupel et al. showing sHLA-E production by
endothelial cells after treatment with IFN-c and TNF-a [29]. Yet,
in opposition to their study, we did not observe any effect of IL-1b
treatment on sHLA-E production by tumor cells, probably due to
a low expression of IL-1 receptor (IL-1R1) by the tumor cell lines
tested in our study. However, as it has been reported that tumor
cell lines, including melanoma cell lines, can express IL-1R1, we
can postulate that IL-1b, which is known to promote matrix
metalloproteinase expression, could increase the production of
sHLA-E by IL-1R1 expressing tumor cells [30,31].
Due to its effect on the proliferation of tumor cells, angiogenesis
and its immunomodulatory capacities, IFN-a is used as immuno-
therapy in the treatment of various solid tumors, as melanoma and
renal carcinoma [32]. Therefore, as we show its ability to
upregulate sHLA-E production by tumor cell lines, systemic
therapy with IFN-a may increase the sHLA-E production in
melanoma patients. In this support, IFN-a therapy is associated
with elevated sHLA-G serum levels in patients with melanoma
[33]. Moreover, it has been reported that c-irradiation downreg-
ulates the surface expression of HLA-G1 on melanoma cells, by
enhancing the proteolytic cleavage of this molecule [34]. So, it will
be interesting to determine if this mechanism is also observed with
HLA-E, which would then be released into the tumor microen-
vironment and hereby affect the local immunological status.
Independently of the possible mechanism of sHLA-E produc-
tion, it is important to highlight how the generation of sHLA-E by
tumor cells could contribute for immunosurveillance escape. Since
interaction of membrane-bound HLA-E with the inhibitory
receptors CD94/NKG2-A induced inhibition of NK and T cell
responses, the immunosuppressor activity of sHLA-E should be
investigated. In support of a potential immunoregulatory fonction,
Coupel et al. reported that sHLA-E protect endothelial cells from
NK-mediated cell lysis [29]. Moreover, sHLA-G and sMICA have
been shown to decrease the immune recognition and destruction
of tumor cells. sHLA-G, via its interaction with inhibitor receptors
ILT-2 and ITL-4, has been shown to inhibit lytic activity of NK
cells, to induce apoptosis of CD8
+ CTL, to affect CD4
+
alloproliferation and to impair NK/DC crosstalk [35–38].
Moreover, the tumor-derived soluble MICA induced endocytosis
and degradation of the cognate activatory receptor NKG2-D on
tumor-infiltrating lymphocytes, impairing their activation [29,39].
Altogether, these data emphasized the importance of tumor-
derived soluble NKR ligands in providing a tumor microenviron-
ment favoring immune escape. Moreover, it has been reported
that sHLA-G are produced in vitro as monomeric and multimeric
forms and that sHLA-G dimerization augments ILT-2-mediated
inhibition of T cell alloresponse [40]. So, the existence of sHLA-E
multimers should also be investigated.
In conclusion, the current study provides for the first time
evidence of an elevated sHLA-E in sera from melanoma patients,
indicating that HLA-E might serve as a clinical marker for the
prognosis or prediction of the clinical outcomes of these cancers
especially in the context of immunotherapy. Because a sensitive
sHLA-E-ELISA has practical advantages for large-scale screening,
it could be adopted for routine use in the immunological follow-up
of melanomas and other human cancers. Although the function of
tumor-derived soluble HLA-E remains to be defined, we can
postulate that these molecules could reinforce the host’s immune
suppression through inhibiting the functions of NK and T cells,
and thereby favor the survival of tumor cells. The clinically
relevant function of these sHLA-E molecules needs to be carefully
analyzed in order to develop appropriate immunotherapeutic
strategies.
Materials and Methods
Antibodies
MEM-E/07 and MEM-E/08 mAbs (Exbio, Czech Republic),
that binds native HLA-E proteins were used for ELISA.
Peptides and Recombinant soluble HLA
Peptides werepurchased from Eurogentec (Angers, France). Purity
(.85%) was controlled by reverse-phase high performance liquid
chromatography. Diverse HLA and b2-microglobulin recombinant
proteins were refolded with the followed indicated synthetic peptides.
HLA-E*0101/VMAPRTLVL (HLA-A*0201 signal peptide) and
HLA-A*0201/AAGIGILTV (Melan-A27–35) monomers were gener-
ated by the recombinant protein facility (IFR 26, Nantes). HLA-
A*2301/PYLFWLAAI, HLA-B*0702/GILGFVFTL, HLA-B*0801/
QAKWRLQTL and HLA-B*2705/HRCQAIRKK monomers were
supplied by the tetramer production facility (Ludwig Institute For
Cancer Research, Lausanne, Switzerland).
Patients and specimens
Sera samples were collected from patients with melanoma
(n=127), all with formal consent. Sera from healthy donors
(n=94) were provided by the Etablissement Franc ¸ais du Sang
(EFS) (Nantes, France) and used as controls.
Ethics Statement
Written consents were obtained from all patients and healthy
donors. All these studies were approved by the local ethics
commmitees ‘‘Comite ´ de Protection des Personnes Ouest IV-
Nantes’’ and the ‘‘Agence Franc ¸aise de Se ´curite ´ Sanitaire des
Produits de Sante ´’’.
Cell lines culture
Melanoma cell lines were established in the GMP Unit of
Cellular Therapy and in our laboratory (UMR 892 INSERM/
Universite ´ de Nantes, France) and belong to the Biocollection PC-
U892-NL (CHU Nantes). Colorectal carcinoma cell lines were
purchased from ATCC or established in our laboratory UMR 892
INSERM/Universite ´ de Nantes (Biocollection PC-U892-FJ, CHU
Nantes). Renal carcinoma cell lines were established in INSERM
U1016/CNRS UMR 8104, Paris, France) [41]. Breast cancer cell
lines were purchased from ATCC or established in our laboratory
UMR 892 INSERM/Universite ´ de Nantes (Biocollection PC-
U892-NG, CHU Nantes). Lung cancer cell lines and mesotheli-
oma cell lines were purchased from ATCC or gifts from M.
Gre ´goire (UMR 892 INSERM/Universite ´ de Nantes, France,
Biocollection PC-U892-MG, CHU Nantes). Myeloma cells lines
were gifts from C. Pellat (UMR 892 INSERM/Universite ´d e
Nantes, France, Biocollection PC-U892-MA, CHU Nantes).
Ovary carcinoma, glioma, leukemia, thyroid, cervix and prostate
cancer cell lines were were purchased from ATCC and kindly
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Universite ´ de Nantes, France). Osteosarcoma cells lines were
purchased from ATCC and gifts from M. Padrines (EA3822,
INSERM U957, Nantes, France). All cell lines were cultured in
RPMI or DMEM with 10% of fetal calf serum (FCS, PAA,
Austria).
Tumor supernatants production
For sHLA-E production screening, 500 000 tumor cells were
cultured in 6-well plates in 3 ml of 10% FCS-RPMI, supplement-
ed or not with IFN-c (20 ng/ml). After 48 hours, tumor
supernatants were collected, centrifuged 5 min at 2500 g and
kept frozen before testing in ELISA.
The impact of others cytokines under sHLA-E production, has
initially been tested at 20 ng/ml during 48 hours with two
melanomas cell lines (M88 and M102) and one colorectal
adenocarcinoma cell line (HT29). Dose-response and kinetics
assessments of IFN-c, IFN-a2a and TNF-a were secondarily
performed as described (concentration ranging from 40 to
0,02 ng/ml during 1 to 6 days) with these three tumors cell lines.
Detection of sHLA-E by ELISA
Nunc-Immuno MaxiSorp Microtiter plates were coated
(50 mL/well) with MEM-E/08 mAb at 1 mg/ml in carbonate/
bicarbonate buffer (CO3HNa 35 mM, CO3Na2 15 mM, pH 9.5)
overnight at 4uC. After four washes with PBS-0.05% Tween 20
(200 mL/well), plates were saturated with PBS containing 10%
FCS for 2 h at room temperature (200 mL/well). After four
washes, the biological samples (50 ml/well optionally diluted in
saturation buffer) were added (in triplicate) and incubated for 2 h
at room temperature. Culture supernatants were assayed undilut-
ed while six doubling dilutions of sera were used. The detecting
biotinylated MEM-E/07 mAb diluted at 1 mg/ml in saturation
buffer was added after four washes (50 mL/well) and incubated
again for 2 h at room temperature. Plates were washed four times
and incubated with strepta-HRP reagent (BD pharmingen) diluted
at 1/1000 in saturation buffer for 1 h at room temperature.
Finally, plates were washed four times and incubated with
substrate (3,39,5,59-tetramethylbenzidine liquid, Sigma, ST Qentin
Fallavier, France) for 30 min at room temperature in the dark
(100 mL/well). The reaction was stopped by addition of 100 mL/
well of 1 M H3PO4. Absorbance was measured at 450 nm with a
Thermo Scientific Multiskan EX. Analysis of the standard curve
and interpolation of samples concentrations were performed using
Prism 5 Software (GraphPad Software Inc., La Jolla, CA, USA).
Statistical analysis
Sera of cancer patients were compared with sera of healthy
donors. According to non-parametric distribution of sHLA-E
serum levels, data were presented as means, medians, ranges and
percentages of positive sHLA-E sera. For the general comparison
of two groups, statistical analysis was performed by Mann-
Whitney U test. Distribution of concentrations across stage was
assessed using Kruskal-Wallis test. To compare the frequency of
positive sHLA-E sera, the Fisher test was used. Statistical analysis
of the modulatory effect of cytokines on sHLA-E production by
tumor cell lines was performed by one-way ANOVA and followed
by post hoc Bonferroni test. A P-value,0.05 was considered
statistically significant. All statistical analyses were performed using
Prism 5 Software (GraphPad Software Inc., La Jolla, CA, USA).
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